About Us

H3 Biomedicine, the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is focused on advancing drugs from bench to bedside. Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 Biomedicine is developing a pipeline of highly targeted medicines that have the potential to impact the future of cancer care and treatment.

 

Our Team

X


Working to realize the promise of precision medicine to help patients with cancer live healthier, longer lives.
X
X
X

Andy Minn, M.D., PH.D.

Andy Minn, M.D., PH.D.

Dr. Andy Minn is a Professor in the Department of Radiation Oncology and an Investigator in the Abramson Family Cancer Research Institute at the University of Pennsylvania. He is also Director of the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at Penn. He received his MD and PhD from the University of Chicago and finished his residency in radiation oncology and his post-doctoral training at Memorial Sloan-Kettering Cancer Center. His research seeks to understand key mechanisms of cancer immunotherapy resistance. Specifically, his work focuses on the role of pattern recognition receptors and interferon signaling pathways, which are pathways that are typically activated when normal cells become infected with a virus. Surprisingly, cancers and many cancer therapies also can activate these pathways, prompting an interest in understanding how this happens, the impact on anti-tumor immunity, and its clinical significance. An overarching goal is to translate this understanding to better inform the design of clinical trials. Dr. Minn’s work has been published in prestigious scientific journals such as Cell and Nature. He is also a member of the American Society for Clinical Investigators (ASCI).

Ping Zhu, PH.D., B.M.

President and Chief Scientific Officer

Ping Zhu, PH.D., B.M.

President and Chief Scientific Officer

Ping joined H3 in 2012 and is currently President and Chief Scientific Officer and serves as an executive leadership team member. Ping brings more than 15 years of experience in cancer research and drug discovery to H3, where he has held positions of increasing scientific and management responsibility. At H3, his group aims to discover next-generation anti-cancer medicines by targeting highly validated molecular targets based upon genomics, transcriptomics and functional data, using systematic approaches. Prior to joining H3, Ping was a group leader at Novartis Institutes for Biomedical Research, where he worked on early drug discovery and target identification and validation in oncology, leading multidisciplinary teams across multiple geographic locations. In 2010, he earned the Novartis Catalyst Award for cancer drug discovery innovation. His research has been published in leading scientific journals including Cell, Nature, Cancer Discovery, Cancer Cell and Nature Communications. Ping was also a recipient of the Endocrine Scholars Award from the Endocrine Society for his scientific achievements.

Ping received his Medical Degree (B.M.) from Shanghai Second Medical University, his Ph.D. in molecular biology from the University of Karlsruhe in Germany and postdoctoral training at the Howard Hughes Medical Institute and UC San Diego.

Ping Zhu, PH.D., B.M.

Ping Zhu, PH.D., B.M.

Ping joined H3 in 2012 and is currently President and Chief Scientific Officer and serves as an executive leadership team member. Ping brings more than 15 years of experience in cancer research and drug discovery to H3, where he has held positions of increasing scientific and management responsibility. At H3, his group aims to discover next-generation anti-cancer medicines by targeting highly validated molecular targets based upon genomics, transcriptomics and functional data, using systematic approaches. Prior to joining H3, Ping was a group leader at Novartis Institutes for Biomedical Research, where he worked on early drug discovery and target identification and validation in oncology, leading multidisciplinary teams across multiple geographic locations. In 2010, he earned the Novartis Catalyst Award for cancer drug discovery innovation. His research has been published in leading scientific journals including Cell, Nature, Cancer Discovery, Cancer Cell and Nature Communications. Ping was also a recipient of the Endocrine Scholars Award from the Endocrine Society for his scientific achievements.

Ping received his Medical Degree (B.M.) from Shanghai Second Medical University, his Ph.D. in molecular biology from the University of Karlsruhe in Germany and postdoctoral training at the Howard Hughes Medical Institute and UC San Diego.

Takashi Owa, PH.D.

Chief Executive Officer

Takashi Owa, PH.D.

Chief Executive Officer

Dr. Takashi Owa currently serves as the President and the Chief Discovery Officer of Eisai Oncology Business Group as well as a member of Board of Directors for Eisai Inc. and a Chairman and CEO for H3 Biomedicine Inc. in the United States. In this role, he is responsible for leading the worldwide R&D operations of Eisai Oncology. Since October 2021, he has also served as a Corporate Officer, a Senior Vice President and the Head of Japan & Asia Medical HQs of Eisai Co., Ltd. in Japan. Dr. Owa joined Eisai as a research scientist in the Oncology Department of Tsukuba Research Laboratories in 1991. Over the years, he has assumed positions of increasing responsibility within R&D operations. Since his relocation to the United States in 2009, He has been in charge of the full product creation cycle from discovery research to clinical development for regulatory approval of innovative oncology drugs in Eisai, including anticancer sulfonamides E7070/indisulam and E7820 as selective protein degraders of the splicing factor CAPER/RBM39, the splicing factor SF3B modulator E7107 as well as two approved drugs Halaven/eribulin (microtubule dynamics inhibitor) and Lenvima/lenvatinib (VEGFR/FGFR/PDGFR/RET/KIT tyrosine kinase inhibitor). He has also been engaged in several open innovation projects, including research and development of the EZH2 inhibitor Tazverik/tazemetostat and the CBP/β-catenin interaction inhibitor E7386 in collaboration with Epizyme and PRISM BioLab, respectively.

Dr. Owa received his Ph.D. in Organic Chemistry, Medicinal Chemistry and Chemical Biology from the University of Tokyo, with particular focus on chemistry and biology of naturally-occurring and man-designed bleomycins. In addition, he studied as a two-year, post-doctoral visiting scientist at Professor Stuart Schreiber’s laboratory in the Department of Chemistry and Chemical Biology, Harvard University, where he focused on chemical biology with histone deacetylase (HDAC) inhibitors as well as the anticancer marine product ecteinascidin 743 (Yondelis/trabectedin) and its synthetic analog phthalascidin 650. Dr. Owa was honored by the Pharmaceutical Society of Japan Division of Medicinal Chemistry, Gilda’s Club New York City and CancerCare with three major awards for his work.

Ross Pettit, M.B.A.

Deputy President

Ross Pettit, M.B.A.

Deputy President

Ross now serves as Deputy President overseeing H3 business functions. Ross joined H3 in Feb 2018 as Vice President of Clinical Operations providing leadership in the Clinical Development team for the planning and execution of H3’s portfolio of target-centric precision oncology medicines. Ross brings more than 30 years of extensive drug development experience to H3. He has focused his career in clinical operations, regulatory affairs, and alliance and portfolio management. During that time Ross has been a key contributor in bringing multiple new drugs to market, across a number of therapeutic areas, and engaging in multiple strategic development alliances and partnerships. Ross has worked extensively in the Americas, Europe and Asia and has held leadership positions with companies including Otsuka, EMD Serono, Coley, ARIAD, AMAG, Infinity and Beigene.

Ross earned an M.B.A. in HealthCare Management from the University of Phoenix and a B.Sc. (Hons) from the University of Kingston, London.

Timothy A. Chan, M.D., PH.D.

Timothy A. Chan, M.D., PH.D.

Timothy A. Chan is a physician scientist, Staff, Professor, and attending physician at the Cleveland Clinic and the Case Comprehensive Cancer Center. He is PI of a cancer genetics laboratory and is an expert in cancer biology and immunogenomics. Dr. Chan is Chair and Founding Director of the Center for Immunotherapy and Precision Immuno-Oncology at the Cleveland Clinic, which focuses on immunotherapy research and developmental therapeutics. He is co-director of the National Center for Regenerative Medicine. Dr. Chan received an MD, a PhD in cancer genetics, completed a residency in radiation oncology, and finished a fellowship at the Johns Hopkins School of Medicine. The Chan laboratory specializes in using genomic analysis to characterize the drivers of genetic programs underlying immunotherapy and oncogenesis. These approaches include large-scale analyses, functional genomics, immunogenomics, biochemical and molecular analyses, and mouse modeling. The lab has a special interest in deciphering the mechanisms underlying immunotherapy treatment response, resistance, and mechanisms. He is an integral part of the clinical teams at the Cleveland Clinic. Dr. Chan was previously at the Memorial Sloan Kettering for over a decade where he was the Paine Webber Chair in Cancer Genetics, a tenured Professor, Director of the Immunogenomics Program, and Vice Chair of the Dept. of Radiation Oncology. He has over 200 publications in journals including Nature, Science, The New England Journal of Medicine, Cell, and others. He is on the scientific advisory board for Cell and the Frederick National Laboratory/National Cancer Institute. He is an NCI Outstanding Investigator and an elected member of the American Association of Physicians (AAP).

Takeshi Hamano, PH.D., M.B.A.

Scientific Operations

Takeshi Hamano, PH.D., M.B.A.

Scientific Operations

Takeshi leads H3’s team of Scientific Operations and was one of the founding members of H3 Biomedicine in 2011, with key contributions to the creation and build-out of key corporate elements and functions. Currently, he is responsible for the management of the entire program portfolio of the company, ranging from discovery to the clinic. Takeshi’s group provides program management and strategic support to all of H3’s programs and platforms. Takeshi began his professional career as a research scientist in drug metabolism and pharmacokinetics at Eisai and contributed to two investigational new drug (IND) filings attained by the team during his tenure. He then transitioned into R&D management after completing his M.B.A. Prior to joining H3, Takeshi served as Senior Director of Portfolio Management for Eisai’s Oncology Business Group where he led portfolio optimization and program prioritization.

Takeshi received his M.B.A. from the Kellogg School of Management at Northwestern University and his Ph.D. and B.A., both in pharmaceutical sciences, from the University of Tokyo.

Brian B. Liau, PH.D.

Brian B. Liau, PH.D.

Brian is an Assistant Professor of Chemistry and Chemical Biology at Harvard University. He obtained his bachelor’s degree in Chemistry and Physics from Harvard College and a PhD in Chemistry from Harvard University. During his PhD studies, Brian completed the chemical synthesis of complex bioactive natural products and investigated their biological mechanism of action. As a postdoctoral fellow at Massachusetts General Hospital, he studied epigenomic mechanisms of adaptation and drug resistance in brain cancer. Currently, his research group is pioneering new approaches that combine chemical biology with genomic technologies to investigate mechanisms in chromatin and cancer biology. Brian is also an Associate Member of the Broad Institute and a recipient of the Ono Pharma Breakthrough Science Initiative Award, the NIH Director’s New Innovator Award, and the Damon Runyon-Rachleff Innovation Award.

Lipika Goyal, M.D., MPHIL

Lipika Goyal, M.D., MPHIL

Lipika Goyal is an Assistant Professor of Medicine at Harvard Medical School and a member of the faculty in Gastrointestinal Medical Oncology at the Massachusetts General Hospital Cancer Center. She completed her undergraduate degree in neuroscience at the University of Pennsylvania and then received a Rhodes Scholarship to pursue a Master of Philosophy in Development Studies at the University of Oxford. She completed her medical degree from Harvard Medical School and then went on to do her residency from the Brigham and Woman’s Hospital and her hematology/oncology fellowship at the Dana Farber/Harvard Cancer Center. She currently leads the Liver Cancer Research Program at MGH, and her research focuses on the development of effective therapies for cholangiocarcinoma and hepatocellular carcinoma. Dr. Goyal has been recognized for her work in understanding clinically acquired FGFR resistance in patients with FGFR2 fusion positive cholangiocarcinoma and identifying sequential strategies of FGFR inhibitors to prolong clinical benefit in these patients. As a clinical trialist and translational scientist, she is the principal investigator of multiple clinical trials and works on drug resistance, biomarker discovery, and immunotherapy in hepatobiliary cancers. She serves on the Steering Committee for NCI Liver Cancer Moonshot Program, and her research is supported by American Cancer Society Clinical Scientist Development Grant, the Department of Defense, the NIH GI SPORE Award, and the Cholangiocarcinoma Foundation Andrea Marie Fuquay Research Fellowship.

Aijalon Pyrtel, M.S.

Human Resources

Aijalon Pyrtel, M.S.

Human Resources

Aija joined H3 in 2015 as the Head of Human Resources. Aija is an accomplished senior human resources professional with over 15 years of experience in the biopharmaceutical industry managing strategic and tactical HR issues. In her current position, she is responsible for leading all HR business transformations, building organizational capabilities, and helping to shape the company’s performance culture. Prior to joining H3, Aija held the position of Human Resources Director, Oncology Translational Medicine unit of Novartis Pharmaceuticals. At Novartis, she provided HR guidance to the Leadership team and Business Partner support to global employee population of 400+ associates; while also disseminating advice and coaching on employee relations issues, salary planning, and retention strategies, and leading the performance management, annual compensation planning and employee development processes for this business division. Aija also served in senior HR management positions at Merck & Co., Inc.

Aija received her Master of Labor Relations degree from the University of Illinois and a B.S. in psychology from Illinois State University.

Myles Brown, M.D.

Myles Brown, M.D.

Myles Brown is Director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute and the Emil Frei III Professor of Medicine at Harvard Medical School. He obtained his undergraduate degree from Yale and his M.D. from Johns Hopkins. Following training in Internal Medicine at the Brigham and Women’s Hospital, a fellowship in Medical Oncology at the Dana-Farber and postdoctoral research at MIT, he joined the staff of the Dana-Farber and the faculty of Harvard Medical School. His research is focused on providing a detailed understanding of the factors underlying the hormone dependence of breast and prostate cancers with the goal of developing new therapies and improving outcomes for patients. He has been recognized for his work identifying the role of co-activators in steroid receptor action; elucidating the dynamic nature of co-regulator function; and defining steroid receptor cistromes. In 2010, together with Shirley Liu he founded the Center for Functional Cancer Epigenetics at the Dana-Farber with the goal of identifying epigenomic alterations in cancer including those that influence response to endocrine therapy. He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Sciences and the American Academy of Arts and Sciences.

Our Story

Since our founding in 2011, H3 has been committed to finding and developing novel potential treatments in our quest to treat cancer.

January 2011

H3 Biomedicine founded by Eisai, $200M funding commitment

August 2011

H3 Biomedicine announces start of scientific operations at Kendall Square

February 2015

H3 and Foundation Medicine announce collaboration to discover novel targets

April 2016

IND Acceptance for Phase 1 H3B-8800 novel splicing modulator in advanced myeloid malignancies

April 2016

IND Acceptance for Phase 1 H3B-6527 FGFR4 inhibitor for HCC

June 2017

IND Acceptance for Phase 1 H3B-6545 novel ER antagonist for ER+ mBrCa

December 2018

H3 and Bristol Myers Squibb begin research collaboration to advance novel therapeutics leveraging H3’s RNA splicing platform

May 2019

IND Acceptance for Phase 1 E7766 STING Agonist

July 2019

H3 joined the Cancer Dependency Map (DepMap) Consortium

Our Relationship with Eisai

H3 is a wholly owned precision oncology research and development subsidiary of the leading global pharmaceutical company, Eisai. With the resource and expertise of a large pharmaceutical company coupled with the agility and innovation of a small biotech, H3 employs an efficient research and development approach to advance programs from discovery to the clinic and aims to deliver impactful therapeutics to patients in need of meaningful new treatment options.

Our Culture

Combining the support of a global pharmaceutical company with the culture of a fast-paced Cambridge, MA biotech, H3 has compounded the best elements of the drug research and development landscape into an environment of productive growth and advancement. Our employees are our single greatest asset and this mindset combined with a collaborative and innovative atmosphere, enables our varied oncology perspectives to flourish and has produced a portfolio of promising discovery and development programs across a variety of cancers and therapeutic approaches. Our diverse strengths enable us to all make a difference in the future of cancer care. 

Roll the Credits

Crafting the proper story requires a diverse cast of characters. This is what H3 says about their…

Favorite Movie

The Holiday
West Side Story (original version)
Tommy Boy
Howl's Moving Castle
Bladerunner
The Princess Bride
Pride and Prejudice (BBC version)
How To Train Your Dragon (or anything Studio Ghibli)
When Harry Met Sally
Star Wars (all of them)
Back to the Future
Roman Holiday
Jurassic Park
The Dark Knight Trilogy
The Martian
Shawshank Redemption
Jaws

Favorite Movie Villain

David Bowie in the Labyrinth
Oddjob
Keyser Soze
Hannibal Lector
Dolores Umbridge
Darth Sidious
Ernst Stavro Blofeld
Maleficent
Loki
Jurassic Park's Velociraptors
Wicked Witch of the West from the Wizard of Oz
Meryl Streep in The Devil Wears Prada
David Bowie in the Labyrinth
Oddjob
Keyser Soze
Hannibal Lector
Dolores Umbridge

Favorite Superhero

Aquaman
Ironman
The Hulk (from the comic book, not the movies)
Spiderman
Iron Man
Spiderman
Rocket Raccoon
Batman
Iron Man
Spiderman
Christopher Reeve as Superman
Deadpool
Spiderman
Aquaman
Ironman
The Hulk (from the comic book, not the movies)
Spiderman

Careers

If you are interested in joining our talented team to work towards making meaningful contributions in the field of cancer therapeutics, consider applying for the open positions listed.

Want to be part of something different?

Connect